Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $8.7680 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Editas Medicine Stock Up 0.9%

Editas Medicine stock opened at $2.20 on Monday. The stock has a 50-day moving average price of $2.02 and a 200 day moving average price of $2.60. The company has a market capitalization of $214.76 million, a price-to-earnings ratio of -0.92 and a beta of 2.16. Editas Medicine has a 52 week low of $0.91 and a 52 week high of $4.54.

Hedge Funds Weigh In On Editas Medicine

Several large investors have recently made changes to their positions in the company. Captrust Financial Advisors purchased a new stake in Editas Medicine during the second quarter worth $26,000. StoneX Group Inc. purchased a new position in Editas Medicine in the fourth quarter valued at $33,000. Victory Capital Management Inc. acquired a new position in shares of Editas Medicine in the third quarter worth about $36,000. Sei Investments Co. purchased a new stake in shares of Editas Medicine during the 3rd quarter worth about $46,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Editas Medicine during the 3rd quarter worth about $57,000. 71.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on EDIT. Weiss Ratings restated a “sell (e+)” rating on shares of Editas Medicine in a research note on Wednesday, January 21st. Chardan Capital raised shares of Editas Medicine from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 13th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Editas Medicine currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.